Dogwood Therapeutics, Inc. (DWTX) stock
DWTXNasdaqPharmaceutical PreparationsFiscal year ends December 31
$1.08+0.00 (0.00%)
Close on Nov 18, 2026Market cap $36.71MP/E –Yield –
Dogwood Therapeutics operating cash flow
Operating cash flow is the cash the business generates from its day-to-day operations.
Dogwood Therapeutics's operating cash flow for the twelve months ending Jun 30, 2026 was -$15.11M. For fiscal 2025 it was -$15.62M. The highest annual figure on record is -$3.90M in fiscal 2020.
Annual operating cash flow
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | -$15.62M | – |
| FY2024 | Dec 31, 2024 | -$8.79M | – |
| FY2023 | Dec 31, 2023 | -$4.87M | – |
| FY2022 | Dec 31, 2022 | -$11.47M | – |
| FY2021 | Dec 31, 2021 | -$15.69M | – |
| FY2020 | Dec 31, 2020 | -$3.90M | – |
Quarterly operating cash flow
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | -$3.61M | – |
| Q1 FY2026 | Mar 31, 2026 | -$4.59M | – |
| Q4 FY2025 | Dec 31, 2025 | -$3.64M | – |
| Q3 FY2025 | Sep 30, 2025 | -$3.27M | – |
| Q2 FY2025 | Jun 30, 2025 | -$4.03M | – |
| Q1 FY2025 | Mar 31, 2025 | -$4.68M | – |
| Q4 FY2024 | Dec 31, 2024 | -$6.13M | – |
| Q3 FY2024 | Sep 30, 2024 | -$910.14K | – |
| Q2 FY2024 | Jun 30, 2024 | -$811.75K | – |
| Q1 FY2024 | Mar 31, 2024 | -$937.41K | – |
| Q4 FY2023 | Dec 31, 2023 | -$1.47M | – |
| Q3 FY2023 | Sep 30, 2023 | -$960.45K | – |
| Q2 FY2023 | Jun 30, 2023 | -$742.41K | – |
| Q1 FY2023 | Mar 31, 2023 | -$1.70M | – |
| Q4 FY2022 | Dec 31, 2022 | -$2.67M | – |
| Q3 FY2022 | Sep 30, 2022 | -$2.48M | – |
| Q2 FY2022 | Jun 30, 2022 | -$3.66M | – |
| Q1 FY2022 | Mar 31, 2022 | -$2.66M | – |
| Q4 FY2021 | Dec 31, 2021 | -$5.18M | – |
| Q3 FY2021 | Sep 30, 2021 | -$2.65M | – |
| Q2 FY2021 | Jun 30, 2021 | -$2.75M | – |
| Q1 FY2021 | Mar 31, 2021 | -$5.11M | – |
| Q4 FY2020 | Dec 31, 2020 | -$2.29M | – |
| Q3 FY2020 | Sep 30, 2020 | -$558.89K | – |
| Q2 FY2020 | Jun 30, 2020 | -$772.57K | – |
| Q1 FY2020 | Mar 31, 2020 | -$277.38K | – |
See a number that looks wrong?